Form 4: Enliven Therapeutics Chief Scientific Officer Exercises Options and Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, exercised stock options to acquire 12,000 shares of common stock at a price of $1.12 per share.
• Simultaneously, Lyssikatos sold 2,352 shares at a weighted average price of $17.7242, 9,577 shares at $18.8038, and 71 shares at $19.3578.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Lyssikatos directly owns 0 shares and indirectly owns 1,117,035 shares through The Lyssikatos Revocable Trust 12/15/2011.
• He also holds options for 260,550 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity under a pre-arranged plan. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies, particularly in the biotech sector where stock options are a significant part of executive compensation.
• Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also see regular Form 4 filings from their executives.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, aligning with industry best practices for compliance and transparency.

Stakeholder Impact

• The sale of shares by a key executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The transactions have a minimal impact on employees, customers, suppliers, and creditors.

Key Dates